Book Review: Textbook of Uncommon Cancer, Second Edition

Publication
Article
OncologyONCOLOGY Vol 15 No 2
Volume 15
Issue 2

The second edition of the Textbook of Uncommon Cancer is a useful resource for practicing oncologists who encounter unusual presentations of common tumors or esoteric subtypes of more common cancers. The text is laid out according to

The second edition of the Textbook of Uncommon Cancer is a useful resource for practicing oncologists who encounter unusual presentations of common tumors or esoteric subtypes of more common cancers. The text is laid out according to organ systems, with each section consisting of multiple chapters either dealing with unusual presentations of common diseases or focusing on rare subtypes of cancer.

In each chapter, where appropriate, the format follows a logical progression from epidemiology, genetics, clinical presentation, imaging, pathology, staging, prognosis, and treatment. For a multiauthored textbook, the chapters are consistently well written and well referenced.

As might be expected, in certain areas involving a distinctly unusual disease, the discussion of disease management is relatively brief. Many of the diseases covered in this textbook are, by definition, rare, and the treatment experience is often anecdotal.

That said, the treatment section of each chapter attempts to collate the experience as cited in the medical literature. Where the experience is anecdotal, the authors make a point of stating so. If a particular treatment strategy can be justified by more powerful evidence, the authors offer an opinion for the best treatment approach.

In most general textbooks of oncology, the topics covered here are dealt with in a few lines or a paragraph. In contrast, the Textbook of Uncommon Cancer provides a resource that covers each of these topics in depth. I have found myself using this book on several occasions since receiving it for review.

Indeed, I believe that the second edition of the Textbook of Uncommon Cancer is a particularly useful text for oncologists who encounter uncommon problems in their practice. With this single resource, physicians will have a better understanding of these unusual cases and be provided with a rational treatment approach-as well as references for more in-depth reading.

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
Related Content